Point of Care Molecular Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.67 Billion |
| Market Size (2029) | USD 5.57 Billion |
| CAGR (2024 - 2029) | 8.77 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Point of Care Molecular Diagnostics Market Analysis
The Global Point-of-Care Molecular Diagnostics Market size is estimated at USD 3.67 billion in 2024, and is expected to reach USD 5.57 billion by 2029, growing at a CAGR of 8.77% during the forecast period (2024-2029).
Molecular diagnostics has been the front runner in the world's response to the COVID-19 pandemic. For instance, in May 2021, a research paper published in the US National Library of Medicine titled 'Point-of-Care PCR Assays for COVID-19 Detection' stated that reverse transcriptase-polymerase chain reaction (RT-PCR) and the quantitative variant (qRT-PCR) have been the gold standard for COVID-19 diagnosis. However, molecular diagnostic technologies have some limitations. For instance, in November 2020, a research paper published in the US National Library of Medicine titled 'Molecular diagnostic technologies for COVID-19: Limitations and challenges' stated that modern molecular diagnostics are not intended for point-of-care diagnosis of COVID-19 but provide a core diagnostic solution to conduct large numbers of tests in a reasonable timeframe. Therefore, an accurate diagnosis of the disease is crucial to curb its spread. Such research studies provide better insight into the applications and limitations of molecular diagnostic technologies. Product launches are another factor in the growth of the market. For instance, in November 2021, Sense Biodetection received USD 65 million in funding to support the anticipated US and European commercial launch of Sense's COVID-19 Test on the company's Veros instrument-free molecular platform.
Point-of-care (POC) molecular testing enables physicians to improve the standard of care by combining quick diagnosis with treatment decisions during the patient's first visit. In past decades, the prevalence of infectious diseases and chronic illnesses like cancer increased. The surging prevalence of chronic illnesses, such as cancer and infectious diseases, is expected to drive the market's growth. For instance, according to the Department of Health & Human Services 2020, about 38 million people were affected by HIV/AIDS in 2019. Therefore, people with HIV are creating a need for point-of-care molecular diagnostics devices for remote locations. As per the March 2020 report of the European Centre for Disease Control and Prevention, 52,862 new tuberculosis cases were reported in 2018 in 30 EU and European Economic Area (EU/EEA) countries, with a notification rate of 10.2 per 100,000 people in the EU/EEA. Out of the total diagnosed cases in 2018, 36,047 cases of tuberculosis were confirmed by culture or smear and nucleic acid amplification test (polymerase chain reaction test). This prevalence has led to increased demand for novel diagnostic methods, further leading to progress in technological advancements and pharmacogenomics. This factor has also increased the demand for POC testing. Such factors are contributing to the market's growth.
However, uncertain reimbursement scenarios have dissuaded many manufacturers from entering the market. A lack of high-complexity test centers to use POC molecular testing is also hindering the market's growth.
Point of Care Molecular Diagnostics Market Trends
This section covers the major market trends shaping the Point-of-Care Molecular Diagnostics Market according to our research experts:
The Oncology Segment is Expected to Register a High CAGR During the Forecast Period
The increasing prevalence of cancer is one of the key reasons for the market's growth. According to the estimates of the Global Cancer Observatory, in 2020, there were 467,965 new cancer cases diagnosed and 185,621 cancer deaths in France.Increasing cancer cases require more diagnoses, thus boosting the point-of-care molecular diagnostics market.
Product launches are driving the market's growth. For instance, in May 2020, a study by the US National Library of Medicine (clinicaltrials.gov) about a trial of one of the point-of-care fecal immunochemical testing devices used in the clinical setting was conducted to see if the results are safe and accurate as a ''rule out'' test for colorectal cancer. The study was sponsored by the Royal Surrey County Hospital NHS Foundation Trust. Many current point-of-care (POC) diagnostics utilize lateral flow immunoassay-based technologies. Lateral flow immunoassays are devices that incorporate antibodies to detect the presence of an analyte like cancer biomarkers. In principle, a lateral flow test is a device that will provide a qualitative answer to the presence of a biomarker in a short time. For instance, in March 2021, Agilent Technologies Inc. entered a definitive agreement to acquire Resolution Bioscience Inc., one of the leaders in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. The acquisition complements and expands Agilent's capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to serve the needs of the fast-growing market. Hence, the demand for these quick detection tests is expected to increase as the incidence of cancer increases.
North America is Expected to Dominate the Market
The prevalence of cancer is the highest in the United States. According to the American Cancer Society, in 2021, there were an estimated 1,898,160 new cancer cases diagnosed and 608,570 cancer deaths in the United States. According to the Global Cancer Observatory, in 2020, there were an estimated 274,364 new cancer cases diagnosed and 86,684 cancer deaths in Canada.The same source also reported that, in 2020, there were an estimated 195,499 new cancer cases diagnosed and 90,222 cancer deaths in Mexico. The prevalence of infectious diseases is also high in the United States and Mexico, creating a high demand for point-of-care diagnostics tests.
However, the United States has a developed and well-structured healthcare system. The system also encourages R&D. These policies encourage global players to enter the United States and the North American market. There has also been a considerable influx of product launches that has boosted the market's growth. For instance, in April 2020, Siemens received FDA clearance for the RapidPoint 500e blood gas analyzer. Such product launch strategies help the company strengthen its point-of-care molecular diagnostics product portfolio. The North American region enjoys the presence of many global market players. As high demand is met by the presence of global players in the region, the market is further expected to increase.
Point of Care Molecular Diagnostics Industry Overview
The point-of-care molecular diagnostics market is consolidated. Global key players develop the majority of point-of-care molecular diagnostic tests. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-Pacific is witnessing the emergence of some small players due to the growing awareness, which has also helped the market to grow. Some of the major players include Abbott Laboratories, Bayer AG, Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Danaher Corporation, and BioMerieux.
Point of Care Molecular Diagnostics Market Leaders
-
Abbott Laboratories
-
Danaher Corporation
-
BioMerieux
-
Bio-Rad Laboratories
-
F. Hoffmann-La Roche Ltd
*Disclaimer: Major Players sorted in no particular order
Point of Care Molecular Diagnostics Market News
- In February 2022, Sense Biodetection entered a strategic agreement with Una Health (Una) for the distribution of the Veros COVID-19 test in the United Kingdom.
- In December 2021, FIND invested USD 21 million in Biomeme, Bioneer, Qlife, and SD Biosensor to accelerate the development, manufacturing, and launch of affordable point-of-care molecular diagnostic platforms that can detect multiple pathogens that cause diseases, including COVID-19.
Point of Care Molecular Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Infectious Diseases and Cancer
- 4.2.2 Rising Demand for Point-of-care Diagnostics
- 4.2.3 Recent Advancements in Technology and Pharmacogenomics
-
4.3 Market Restraints
- 4.3.1 Uncertain Reimbursement Scenario
- 4.3.2 Need for High-complexity Testing Centers
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Application
- 5.1.1 Infectious Diseases
- 5.1.2 Oncology
- 5.1.3 Hematology
- 5.1.4 Prenatal Testing
- 5.1.5 Endocrinology
- 5.1.6 Other Applications
-
5.2 By Technology
- 5.2.1 PCR
- 5.2.2 Genetic Sequencing
- 5.2.3 Hybridization
- 5.2.4 Microarray
-
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Homecare
- 5.3.3 Other End Users
-
5.4 By Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 Siemens Healthineers
- 6.1.3 F. Hoffmann-La Roche Ltd
- 6.1.4 Becton, Dickinson and Company
- 6.1.5 Danaher Corporation
- 6.1.6 BioMerieux
- 6.1.7 Agilent Technologies
- 6.1.8 OraSure Technologies Inc.
- 6.1.9 Thermo Fisher Scientific
- 6.1.10 Meridian Bioscience Inc.
- 6.1.11 Co-Diagnostics Inc.
- 6.1.12 Biocartis
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPoint of Care Molecular Diagnostics Industry Segmentation
Point-of-care molecular tests check for certain changes in a gene or chromosome that may cause or affect the chance of developing a specific disease or disorder, such as cancer, at or near the point-of-care, i.e., at the time and place of the patient care. The point-of-care molecular diagnostics market is segmented by application (infectious diseases, oncology, hematology, prenatal testing, endocrinology, and other applications), technology (PCR, genetic sequencing, hybridization, and microarray), end user (hospitals, homecare, and other end users), geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Application | Infectious Diseases | |
| Oncology | ||
| Hematology | ||
| Prenatal Testing | ||
| Endocrinology | ||
| Other Applications | ||
| By Technology | PCR | |
| Genetic Sequencing | ||
| Hybridization | ||
| Microarray | ||
| By End User | Hospitals | |
| Homecare | ||
| Other End Users | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Point of Care Molecular Diagnostics Market Research FAQs
How big is the Global Point-of-Care Molecular Diagnostics Market?
The Global Point-of-Care Molecular Diagnostics Market size is expected to reach USD 3.67 billion in 2024 and grow at a CAGR of 8.77% to reach USD 5.57 billion by 2029.
What is the current Global Point-of-Care Molecular Diagnostics Market size?
In 2024, the Global Point-of-Care Molecular Diagnostics Market size is expected to reach USD 3.67 billion.
Who are the key players in Global Point-of-Care Molecular Diagnostics Market?
Abbott Laboratories, Danaher Corporation, BioMerieux, Bio-Rad Laboratories and F. Hoffmann-La Roche Ltd are the major companies operating in the Global Point-of-Care Molecular Diagnostics Market.
Which is the fastest growing region in Global Point-of-Care Molecular Diagnostics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Point-of-Care Molecular Diagnostics Market?
In 2024, the North America accounts for the largest market share in Global Point-of-Care Molecular Diagnostics Market.
What years does this Global Point-of-Care Molecular Diagnostics Market cover, and what was the market size in 2023?
In 2023, the Global Point-of-Care Molecular Diagnostics Market size was estimated at USD 3.37 billion. The report covers the Global Point-of-Care Molecular Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Point-of-Care Molecular Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Point of Care Molecular Diagnostics Industry Report
The POC Molecular Diagnostics Market is segmented by application, technology, end user, and geography. This industry report provides a comprehensive market analysis, highlighting the market share and market size across various segments. The market research covers applications such as infectious diseases, oncology, haematology, prenatal testing, endocrinology, and other applications. The technology segment includes PCR, genetic sequencing, hybridization, and microarray. End users are categorized into hospitals, homecare, and other end users.
The market trends indicate a significant market growth, driven by advancements in technology and increasing demand for rapid diagnostic solutions. The industry overview highlights the market leaders and their contributions to the market value. The market forecast provides insights into the future market outlook, with a detailed market review and market predictions.
The industry analysis includes an examination of the market segmentation by geography, covering North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. The report also includes a report example and a free report PDF download for further reference.
The industry statistics and industry information presented in the report offer a detailed understanding of the market dynamics. The industry trends and market data are crucial for stakeholders to make informed decisions. The industry outlook and market overview provide a clear picture of the current market scenario and future growth prospects.
The report also covers industry sales and industry size, emphasizing the market's potential and opportunities. The market segmentation and market value are analyzed to identify key growth areas. Overall, this report serves as a valuable resource for industry research and provides a comprehensive understanding of the POC Molecular Diagnostics Market.
